LFG
LENZ

Larson Financial Group’s LENZ Therapeutics LENZ Stock Holding History

Larson Financial Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$522 Buy
57
+44
+338% +$618 ﹤0.01% 3309
2025
Q4 		$208 Sell
13
-165
-93% -$4.81K ﹤0.01% 3265
2025
Q3 		$8.29K Buy
178
+18
+11% +$662 ﹤0.01% 2113
2025
Q2 		$4.69K Buy
160
+121
+310% +$3.29K ﹤0.01% 2095
2025
Q1 		$1K Buy
+39
New +$960 ﹤0.01% 2389

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Larson Financial Group's LENZ Position: Q1 2026 in Review

Larson Financial Group increased its LENZ Therapeutics (LENZ) stake by 338% in Q1 2026, buying an estimated $618 and bringing the position to 57 shares worth $522. The position accounts for ﹤0.01% of the portfolio, ranked #3309.

Larson Financial Group first reported a position in LENZ in Q1 2025 and has held it in 5 quarters since. The position peaked at $8.29K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Larson Financial Group held 57 shares of LENZ Therapeutics worth $522 as of Q1 2026.
  • Larson Financial Group bought 44 LENZ Therapeutics shares in Q1 2026, an estimated $618.
  • LENZ Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3309 holding.
  • Larson Financial Group first reported a position in LENZ Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Larson Financial Group's LENZ Therapeutics position peaked at $8.29K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.